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Abstract
 
Defensins, antimicrobial peptides of the innate immune system, protect human mucosal epi-
thelia and skin against microbial infections and are produced in large amounts by neutrophils.
 
The bacterial pathogen 
 
Staphylococcus aureus
 
 is insensitive to defensins by virtue of an unknown
resistance mechanism. We describe a novel staphylococcal gene, 
 
mprF
 
, which determines resis-
tance to several host defense peptides such as defensins and protegrins. An 
 
mprF
 
 mutant strain
was killed considerably faster by human neutrophils and exhibited attenuated virulence in
mice, indicating a key role for defensin resistance in the pathogenicity of 
 
S. aureus
 
. Analysis of
membrane lipids demonstrated that the 
 
mprF
 
 mutant no longer modifies phosphatidylglycerol
 
with 
 
l
 
-lysine. As this unusual modification leads to a reduced negative charge of the mem-
brane surface, MprF-mediated peptide resistance is most likely based on repulsion of the cat-
ionic peptides. Accordingly, inactivation of 
 
mprF
 
 led to increased binding of antimicrobial
peptides by the bacteria. MprF has no similarity with genes of known function, but related
genes were identified in the genomes of several pathogens including 
 
Mycobacterium tuberculosis
 
,
 
Pseudomonas aeruginosa
 
, and 
 
Enterococcus faecalis
 
. MprF thus constitutes a novel virulence factor,
which may be of general relevance for bacterial pathogens and represents a new target for at-
tacking multidrug resistant bacteria.
 
Key words: host defense peptides • oxygen-independent killing • 
 
Staphylococcus aureus
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recent appearance of strains with reduced susceptibility to
vancomycin, the antibiotic of last resort, raises the specter
of untreatable staphylococcal infections and adds urgency
to the search for new antiinfective strategies (2).
 
R.W. Jack’s present address is Department of Biology and Chemistry,
City University of Hong Kong, 83 Tat Chee Ave., Kowloon Tong,
Kowloon, Hong Kong.
M. Otto’s present address is Laboratory of Human Bacterial Pathogen-
esis, National Institute of Allergy and Infectious Diseases, National Insti-
tutes of Health, 903 South 4th St., Hamilton, MT 59840.
 
Address correspondence to Andreas Peschel, Microbial Genetics, Uni-
versity of Tuebingen, Auf der Morgenstelle 28E, 72076 Tuebingen,
Germany. Phone: 49-7071-297-2611; Fax: 49-7071-29-5065; E-mail:
andreas.peschel@uni-tuebingen.de
 
Introduction
 
The human pathogen 
 
Staphylococcus aureus
 
 is a major cause
of community- and hospital-acquired skin, respiratory, en-
dovascular, soft tissue, bone, and joint infections (1). The
increasing prevalence of multidrug resistant strains and the 
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S. aureus
 
 has evolved the means to resist antimicrobial
host components such as lysozyme, the 
 
a
 
-defensins human
neutrophil peptide (HNP)1–3 (3), and the 
 
b
 
-defensin
hBD2 (4). Defensin peptides constitute a shield against mi-
crobial infections on skin, on epithelia of the respiratory,
gastrointestinal, and genitourinary tracts (
 
b
 
-defensins), and
are found in large amounts in the granules of phagocytes
and intestinal Paneth cells (
 
a
 
-defensins; reference 5). Al-
though defensins account for 50% of the neutrophil granule
proteins, they fail to kill 
 
S. aureus
 
 effectively. Accordingly,
patients with inherited oxidative burst deficiency (chronic
granulomatous disease [CGD]) are particularly susceptible
to 
 
S. aureus
 
 infections (6). When keratinocytes from human
skin come into contact with bacterial pathogens, they up-
regulate the expression of the defensin hBD-2 gene (4) and
there is evidence that airway epithelial cells respond in a
similar manner (7). Diminished defensin activity, caused by
increased salt concentration in airway fluids, is thought to
contribute to the susceptibility of cystic fibrosis patients to
life-threatening 
 
S. aureus
 
 and 
 
Pseudomonas aeruginosa
 
 infec-
tions (8). The ability of bacterial pathogens to resist host de-
fense peptides has a profound influence on their virulence as
demonstrated for 
 
Salmonella typhimurium
 
 (9). However, the
molecular basis for defensin resistance has remained elusive.
Defensins form pores in the bacterial cytoplasmic mem-
brane (5); peptides with similar properties and activity have
been found in several vertebrates and invertebrates as well
as in plants (10) and bacteria (11). They include molecules
with 
 
b
 
-sheet structure such as porcine protegrins (12),
 
a
 
-helical peptides such as the amphibian magainins (13),
and the bacterial lantibiotics bearing thioether bridges (11).
Both 
 
S. aureus
 
 and the coagulase-negative 
 
Staphylococcus xy-
losus
 
 show high level innate tolerances to host defense pep-
tides and lantibiotics.
 
Materials and Methods
 
Transposon Mutagenesis and DNA Sequence Analyses.
 
All bac-
terial strains were grown in BM broth (1% tryptone, 0.5% yeast
extract, 0.5% NaCl, 0.1% K
 
2
 
HPO
 
4
 
, and 0.1% glucose) unless
otherwise noted. A mutant library of 
 
S. xylosus
 
 C2a was con-
structed using transposon Tn917 and the delivery vector pTV1ts
as described previously (3). Mutant clones (4,000) were trans-
ferred to BM agar plates containing 3 
 
m
 
g gallidermin/ml and
monitored for impaired growth. Tn917-specific primers were
used to sequence genomic DNA upstream and downstream from
the transposon insertion site by cycle sequencing (14) and the se-
quence was completed by primer walking. With one of the prim-
ers used for sequencing of the 
 
S. xylosus
 
 
 
mprF
 
, part of the corre-
sponding gene in 
 
S. aureus
 
 Sa113 was obtained and the sequence
was completed by primer walking. The program tblastn with the
Microbial Genomes Blast Databases at http://www.ncbi.nlm.
nih.gov was used to perform sequence similarity searches. Pre-
diction of the MprF transmembrane topology was accomplished
using the program TMAP at http://www.mbb.ki.se/cgi-bin/
tmap1.pl. It is based on a multiple alignment of the closely related
MprF homologues from 
 
S. aureus
 
, 
 
S. xylosus
 
, 
 
Bacillus subtilis
 
, and
 
Enterococcus faecalis
 
.
 
Construction of Plasmids and Homologous Recombination.
 
For in
vitro recombination of DNA, standard methods and vectors were
 
used (14). To delete the 
 
mprF
 
 gene of 
 
S. aureus 
 
Sa113, DNA frag-
ments of 885 bp and 1,042 bp flanking 
 
mprF
 
 were amplified by
PCR and cloned together with the 
 
ermB
 
 gene from Tn551 into
the polylinker of the temperature-sensitive shuttle plasmid pBT2
using the restriction sites indicated in Fig. 1 A. After construction
in 
 
Escherichia coli
 
 DH5a (14), the resulting plasmid pBT
 
D
 
mprF
was transferred to 
 
S. aureus
 
 Sa113 by electroporation (15) and
 
mprF
 
 deletion mutants were enriched by incubation at 42
 
8
 
C in
the presence of 2.5 
 
m
 
g/ml erythromycin; the recombination pro-
cedure has recently been described in detail (16). The proper in-
tegration of 
 
ermB
 
 was verified by sequencing of the genomic
DNA at the borders of the PCR-derived regions. A 2,345-bp
fragment comprising 93% of the 
 
mprF
 
 gene was deleted. Plasmid
pRBmprF was constructed in 
 
E. coli
 
 DH5
 
a
 
 by ligation of a
3,281-bp PCR fragment bearing the 
 
mprF
 
 gene of 
 
S. xylosus
 
 C2a,
together with 359 bp upstream containing the putative promoter
region and 400 bp downstream containing the terminator struc-
ture into the SmaI site of the shuttle vector pRB473 (17). To
construct plasmid pTXmprF, a 2,927-bp PCR fragment encod-
ing the 
 
S. xylosus
 
 
 
mprF
 
 gene was cloned in the expression vector
pTX15 via BamHI and MluI to produce a transcriptional fusion
with the 
 
xylA 
 
promoter (18). PCR primers were modified to in-
troduce a BamHI site 34 bp upstream of the 
 
mprF
 
 start codon and
a MluI site 370 bp downstream of the stop codon. The cloning
host 
 
Staphylococcus carnosus
 
 TM300 was transformed with the
pTXmprF ligation mixture by protoplast transformation (19).
Plasmids pRBmprF and pTXmprF were subsequently transferred
to 
 
S. aureus
 
 Sa113 or 
 
S. xylosus
 
 C2a by electroporation (15). The
 
xylA
 
 promoter of pTXmprF is repressed by the plasmid-encoded
repressor XylR and derepression was achieved by the addition of
0.5% xylose to the culture medium (18).
 
Antimicrobial Peptides and Antibacterial Assay.
 
Defensin
HNP1-3 was isolated from human peripheral blood neutrophils
by extraction of the neutrophil granules with 5% acetic acid and
subsequent reversed phase HPLC (RP-HPLC)
 
1
 
 separation ac-
cording to established methods (3, 20). The resulting product
comprised the three defensin variants HNP1, HNP2, and HNP3,
differing only in the first amino acid position. Protegrins 3 and 5
and tachyplesin 1 were synthesized as peptide amides, oxidized to
obtain the correct disulfide bridges, and purified by RP-HPLC
(purities 
 
.
 
95%), as recently described (3). The fluorescent-
labeled derivative Lys(
 
e
 
Dns)-tachyplesin 1 was synthesized, folded,
and purified as above with the exception that the NH
 
2
 
 terminus
was extended by a further lysine residue, the 
 
e
 
-amino group of
which was dansylated. The purity and quality of the peptide
preparations was confirmed by HPLC and electrospray ionization
mass spectrometry (ESI-MS). Gallidermin was provided by Dr.
K. Thomae (GmbH, Biberach, Germany). Nisin, synthetic
(A
 
8,13,18
 
)-magainin II amide, melittin, gramicidin S, and gramici-
din D were purchased from Sigma-Aldrich. Minimal inhibitory
concentration (MIC) values of the various peptides were deter-
mined in serial dilution tests using Luria-Bertani (LB) broth (1%
tryptone, 0.5% yeast extract, 0.5% NaCl) as described recently
(21). As the activity of human defensins is very sensitive to the salt
concentration (20), half-strength LB broth without NaCl was
used for them; the tested strains all grew well in this medium.
 
1
 
Abbreviations used in this paper:
 
 DPG, diphosphatidylglycerol; FT-ICR,
Fourier transform ion cyclotron resonance; GC, gas chromatography;
HNP, human neutrophil peptide; HSA, human serum albumin; L-PG,
lysylphosphatidylglycerol; MIC, minimal inhibitory concentration; MPO,
myeloperoxidase; MS, mass spectrometry; PG, phosphatidylglycerol; RP-
HPLC, reversed phase HPLC; 2d-TLC, two-dimensional TLC. 
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Phagocytosis and Killing of S. aureus by Human Neutrophils.
 
Blood was drawn from healthy human volunteers and heparin-
ized. Neutrophils were isolated from peripheral blood as de-
scribed previously (22) and resuspended in HBSS-HSA (HBSS
containing 0.05% human serum albumin). To prepare bacteria for
killing experiments, Mueller Hinton Broth was inoculated with
1/100 volumes of overnight cultures and vigorously shaken at
37
 
8
 
C until mid-logarithmic phase was reached. The bacteria were
washed twice in HBSS-HSA and adjusted to a density of 8.5 
 
3
 
10
 
7
 
 CFU/ml. Normal human serum was added to a final concen-
tration of 4% and bacteria were opsonized for 10 min at 37
 
8
 
C.
Prewarmed bacterial and neutrophil suspensions were mixed to
final concentrations of 8.5 
 
3
 
 10
 
4
 
 CFU/ml and 5 
 
3
 
 10
 
6
 
 neutro-
phils/ml. 50-
 
m
 
l samples were shaken at 37
 
8
 
C and incubation was
stopped by the addition of 2 ml ice-cold distilled water to disrupt
the neutrophils. Appropriate sample volumes were spread on LB
agar plates and colonies were counted after 24 h incubation at
37
 
8
 
C. When bacteria were incubated for 4 h under the same con-
ditions without neutrophils, no significant changes in the colony
numbers compared with the initial counts were observed.
In phagocytosis studies, bacteria were grown as described
above, washed, resuspended in PBS, and inactivated by heating
for 25 min at 70
 
8C. Subsequently, 0.1 mg/ml FITC was added
and the bacteria were labeled at 378C for 5 h. After washing with
PBS, the bacteria were resuspended in HBSS-HSA, adjusted to
the same density, and opsonized as described above. 50-ml ali-
quots of the prewarmed bacterial and neutrophil suspensions
were mixed and shaken at 378C. The final concentrations of bac-
teria and neutrophils were 8.5 3 107/ml and 2.5 3 106/ml, re-
spectively. Incubation was stopped by addition of 100 ml ice-cold
1% paraformaldehyde. The percentage of neutrophils bearing
FITC-labeled bacteria was determined by flow cytometric analy-
sis of 5,000 cells using a FACScan™ (Becton Dickinson).
Killing by Myeloperoxidase. Bacteria were grown as described
for neutrophil-mediated killing and washed twice with PBS con-
taining 0.0005% HSA. 3 3 105 CFU/ml were incubated with
0.05 U myeloperoxidase (MPO)/ml (Calbiochem) and 10 mM
H2O2 in the same buffer after preheating all solutions to 378C.
154 mM NaCl from the PBS buffer was present in the samples to
permit generation of toxic chlorinating compounds (23). Samples
of 10 ml each were shaken at 378C and killing was stopped after
45 min by 25-fold dilution in ice-cold PBS. CFUs were counted
24 h after plating appropriate amounts on LB agar.
Animal Studies. Female NMRI mice aged 5–7 wk were in-
jected in the tail vein with a bacterial suspension containing 1.8 3
107 CFU of either S. aureus Newman wild type or the isogenic
mprF mutant and evaluated for weight loss, arthritis, and sepsis
over a 7-d period as described previously (24). Mice were subse-
quently killed and kidneys were removed in order to assay bacte-
rial loads. The differences between the means of the values in all
groups were tested for significance with the two-tailed Student’s t
test. The between-group differences in the mortality rate, fre-
quency of arthritis, body weight losses, and bacterial counts in
kidneys were analyzed using the chi-square test. A P value #
0.05 was considered statistically significant. All mice were treated
in accordance with institutional guidelines.
Isolation and Detection of Membrane Lipids. Bacteria were
grown overnight in BM broth containing 0.25% glucose, washed
once in sodium acetate buffer (20 mM, pH 4.5), and disrupted in
the same buffer using glass beads and a Disintegrator S (Biomatic
GmbH) as described elsewhere (18). Polar lipids were extracted
by the Bligh-Dyer procedure (25), vacuum dried, and dissolved
in chloroform/methanol (2:1, by volume). Two-dimensional
TLC (2d-TLC) was carried out as described previously (26). In
brief, equal amounts of lipid extracts were spotted onto silica 60
F254 HPTLC plates (Merck) and developed with chloroform/
methanol/water (65:25:4, by volume) in the first direction and
chloroform/acetic acid/methanol/water (80:15:12:4, by vol-
ume) in the second direction. All lipids were visualized with mo-
lybdatophosporic acid spray (Merck) followed by charring at
1208C and treatment with ammonia vapor to improve the con-
trast. Phospholipids or amino group–containing lipids were selec-
tively stained with Molybdenum Blue (Sigma-Aldrich) or ninhy-
drin spray (Merck), respectively. For further analyses, lipid spots
were stained with iodine vapor, scraped from the glass plates, and
extracted with dichloromethane/methanol (2:1, by volume).
Phosphatidylglycerol (PG) and diphosphatidylglycerol (DPG)
were purchased from Sigma-Aldrich and used as standards to de-
termine the positions of the PG and DPG spots in 2d-TLC.
Lipid Analysis by Mass Spectrometry and Gas Chromatography.
The masses of lipids from the TLC spot were determined by
Fourier transform ion cyclotron resonance (FT-ICR) mass spec-
trometry (MS) on an Apex II FT-ICR mass spectrometer
(Bruker) in both the positive and negative ESI modes. To analyze
the composition of the lipid, the samples were spiked with
n-tridecanoic acid and d-lysine as internal standards and incu-
bated at 1108C for 30 min in 200 ml 1.5 M ethanolic HCl. After
addition of 200 ml distilled water, the hydrophobic compounds
were extracted into pentane and subsequently analyzed by gas
chromatography (GC) and GC-MS on an Agilent 6890/5973
(Agilent Technologies) and an HP-5 MS capillary (30 m 3 0.25 mm).
Figure 1. Inactivation of mprF (A), Kyte and Doolittle hydrophobicity
profile (B), and putative transmembrane topology (C) of the S. aureus
MprF. (A) The deletion caused by Tn917 integration in the S. xylosus
mutant XG2 is indicated by the triangle. The mprF gene of S. aureus was
disrupted by replacing the mprF gene with the erythromycin resistance
gene ermB. T, transcriptional terminator. (C) The positions in the MprF
sequence of putative transmembrane segments and the numbers of posi-
tive residues in the putative loops are indicated.1070 Staphylococcus aureus Resistance to Defensins via a Novel Virulence Factor
The ethanolic phase was evaporated to dryness, reesterified with
ethanolic HCl to ensure complete esterification, and then trifluo-
roacetylated (trifluoroacetic anhydride/dichloromethane 4:1 at
1108C for 10 min). The derivatized amino acids were detected by
chiral GC-MS on a Lipodex E capillary and determined by enan-
tiomer labeling (27). Finally, the ethanolic layer was trimethylsi-
lylated (bis[trimethylsilyl]trifluoroacetamide in pyridine [1:1]) at
608C for 30 min and derivatives were analyzed by GC-MS on the
HP-5 MS capillary. A sector from a TLC plate without sample
but identically developed and worked up (blank) was used to cor-
rect the fatty acid amounts determined in corresponding spots
from sample-containing plates.
Interaction of Tachyplesin 1 and Gallidermin with Bacterial Cells.
Strains were grown for 5 h in BM medium, harvested, washed
three times, and resuspended in ice-cold 50 mM sodium phos-
phate buffer, pH 7.0. Bacteria (2 3 107/ml) were incubated with
2 mM Lys(eDns)-tachyplesin 1 for 20 min on ice, and pelleted by
centrifugation. The relative fluorescence of the supernatant was
determined spectrofluorometrically using excitation and emission
wavelengths of 340 and 522 nm, respectively. Binding of gallider-
min was analyzed in a similar way with the following modifica-
tions: bacteria were grown in LB broth with 0.5% xylose, incu-
bated with 2.3 mM (S. aureus) or 11.5 mM (S. xylosus) gallidermin
for 20 min at 378C, and the bacterial density was 1.6 3 108/ml.
The amount of gallidermin in the supernatant was determined by
RP-HPLC as described previously (3).
Results
Identification of the mprF Gene and Its Influence on Suscepti-
bility to Antimicrobial Peptides. Transposon Tn917 inser-
tion mutants of S. xylosus C2a were analyzed for sensitivity
to the lantibiotic gallidermin. Mutant XG2 showed severely
impaired growth on gallidermin agar plates, whereas
growth was normal in the absence of the peptide. The
transposon insertion had inactivated an open reading frame
of 2,525 bp (Fig. 1 A). The corresponding gene from S. au-
reus Sa113 was sequenced and found to encode a predicted
protein of 841 amino acids without similarity to any pro-
teins of known function. The S. aureus and S. xylosus pro-
teins share 80% similarity and were named MprF (“multiple
peptide resistance factor”). The highly hydrophobic NH2-
terminal regions are predicted to contain 13 transmembrane
segments, whereas the COOH-terminal domains are hy-
drophilic and probably located at the outside of the cyto-
plasmic membrane (Fig. 1, B and C). Upstream of mprF,
orf1 encodes a membrane protein with 57 and 54% identity
to proteins of unknown function from the genomes of
Streptococcus mutans and Streptococcus pneumoniae, respectively
(Fig. 1 A). The reading frame downstream of the S. aureus
mprF shares up to 67% similarity with the methionine sul-
foxide reductase genes (msrA) of various bacteria. msrA has
recently been shown to play an important role in the bacte-
rial defense against respiratory burst components in S. pneu-
moniae, Neisseria gonorrhoeae, and E. coli (28). It is followed
by a putative transcriptional regulator gene (orf2) which has
significant similarities to the enterococcal repressor gene psr
involved in b-lactam resistance (29). In terms of growth
and microscopic appearance, the mprF mutant was indistin-
guishable from the wild type (data not shown).
The S. aureus mprF gene was replaced by an erythromy-
cin resistance gene (ermB) via homologous recombination
Figure 2. MIC values of the indicated
antimicrobial peptides against S. aureus wild
type and mprF mutant bearing the empty
control plasmid pRB473 or the comple-
mentation vector pRBmprF. Positively or
negatively charged peptide positions are
highlighted in black or gray, respectively.
The charges of amino acid side chains and
the terminal amino and carboxyl groups
were considered. *Although human de-
fensin HNP-1 is shown, a mixture of
HNP1, HNP2, and HNP3 which differ in
the first amino acid was used in the antibac-
terial assay. ‡We used and show the syn-
thetic variant A8,13,18-magainin II amide.
§MICs of the fluorescent derivative
Lys(eDns)-tachyplesin 1. Unusual amino
acids: Lan, lanthionine; Mla, methyl-
lanthionine; Dhb, dehydrobutyrine; Avc,
S-aminovinyl-d-cysteine; Dha, dehydroala-
nine; O, ornithine.1071 Peschel et al.
(Fig. 1 A). In the absence of an intact mprF gene, the sus-
ceptibility of S. aureus Sa113 to defensin HNP1-3 from hu-
man neutrophils, protegrins 3 and 5 from porcine leuko-
cytes, and tachyplesin 1 from horseshoe crab haemocytes
was 8- to at least 30-fold higher (Fig. 2). The sensitivity to
the lanthionine-containing peptides (lantibiotics) gallider-
min from Staphylococcus gallinarum and to nisin from Lactoba-
cillus lactis (11) was increased by factors of 8 to 38. The lin-
ear peptides magainin II from clawed frog skin and melittin
from honeybee venom (13) were only slightly more active
against the mprF mutant (three- to fourfold). The increased
sensitivity of the mutant seemed to be restricted to ex-
tended cationic peptides, as the small, circular gramicidin S
and the linear, neutral gramicidin D (both peptides from
Bacillus brevis; reference 30) were almost equally active
against wild-type and mutant strains. Interestingly, even the
wild-type strain was particularly susceptible to these pep-
tides. Complementation of the mprF mutant with plasmid
pRBmprF resulted in normal or considerably higher toler-
ances to cationic antimicrobial peptides (Fig. 2).
The mprF Mutant Is Killed Faster by Human Neutrophils
than the Wild-Type Strain. The kinetics of killing by hu-
man neutrophils for S. aureus Sa113 wild-type and mprF
mutant strains were compared. Log-phase bacteria were
opsonized with normal human serum and incubated with
neutrophils for various time intervals. Subsequently, the
numbers of resistant bacteria were determined. The mprF
mutant was killed considerably faster than the wild type
(Fig. 3 A). A 50% reduction in the number of applied wild-
type or mutant bacteria was noted after 100 and 22 min,
respectively. The uptake kinetics of the two strains revealed
no differences (Fig. 3 B), suggesting that the faster killing of
mutant bacteria results from an increased susceptibility to
neutrophil antimicrobial activities rather than increased
phagocytosis.
As normal neutrophils use oxygen-dependent killing
mechanisms in addition to defensins, we compared, using
human neutrophil MPO, the rates of inactivation of S. au-
reus Sa113 wild type and mprF mutant. Bacteria were incu-
bated with MPO in the presence of H2O2 and chloride
ions to permit generation of toxic oxidizing and halogeniz-
ing products (23). The kinetics of killing by MPO revealed
no significant differences: 38.3 6 4.8% and 36.0 6 16%
(means and SD of five counts from a representative experi-
ment) of wild-type and mutant bacteria, respectively, were
inactivated after 45 min incubation indicating that im-
proved killing of the mprF mutant by neutrophils results
from increased susceptibility to oxygen-independent
mechanisms rather than to respiratory burst.
Disruption of mprF Results in Attenuated Virulence. The
virulence of the mprF mutant was analyzed in a mouse
model of sepsis and septic arthritis (24) using S. aureus
Newman, which is more virulent than the laboratory strain
Sa113. The mprF mutation caused a similar sensitivity to
antimicrobial peptides in strain Newman as in strain Sa113
(data not shown). Significant differences in the mortality of
NMRI mice injected intravenously with 1.8 3 107 CFU
bacteria were noted, with 33% mortality in the wild-type
infected group and no deaths in the mutant infected group
at day 7 after infection (Table I). The incidence of arthritis
in the two groups of animals was also different. At day 7 af-
ter infection, the frequencies of joint swelling were 21% for
the mutant and 94% for the wild type. In addition, the
wild-type infected animals lost significantly more weight
during the course of the experiment than the mutant
group, and the numbers of bacteria recovered from the
kidneys of mice infected with the mprF mutant were signif-
icantly lower than those from wild-type infected animals
(Table I), suggesting that the mprF mutant causes less sys-
temic effects of disease.
mprF Is Involved in Esterification of Membrane PG with
L-Lysine. To analyze whether mprF-dependent peptide
resistance is based on modification of the target site, the cy-
toplasmic membrane, we compared the membrane lipid
patterns of the wild-type and mutant strains by 2d-TLC
analysis. One of the prominent and one minor lipid spot
Figure 3. Kinetics of killing and phagocytosis of wild-type (d) and
mprF mutant bacteria (s) by neutrophils. (A) The numbers of viable bac-
teria (CFU) after incubation with neutrophils are expressed as percentage
of the initial counts (means and SD of three counts from a representative
experiment). (B) The percentage of neutrophils bearing FITC-labeled S.
aureus cells are given (means and SD of four independent experiments).
Table I. Comparative Virulence in NMRI Mice of S. aureus 
Newman Wild Type and mprF Mutant
Strain
Days
after
infection Mortality Arthritis
Weight
loss*
Bacterial
loads
in kidneys*
no. dead
mice/total no.
no. positive
mice/total no. g 3108 CFU
Wild type 3 2/24 12/22 5.1 6 1.0 ND
mprF mutant 3 0/24‡ 5/24‡ 1.9 6 1.8§ ND
Wild type 7 8/24 15/16 8.4 6 1.7 5.9 6 4.9
mprF mutant 7 0/24i 5/24§ 4.1 6 2.7§ 1.1 6 1.3§
*Values shown are the mean 6 SD.
‡Not significant.
§Value is significantly different (P , 0.0001) compared with the wild
type at the same time point after infection.
iValue is significantly different (P , 0.05) compared with the wild type
at the same time point after infection.1072 Staphylococcus aureus Resistance to Defensins via a Novel Virulence Factor
were lacking in the mprF mutant but reappeared upon
complementation with plasmid pRBmprF (Fig. 4 A). The
lipids in question stained positive with Molybdenum Blue
and ninhydrin reagents (data not shown) indicating that
they represent amino group–containing phospholipids.
Previous analyses have revealed that PG and derivatives
thereof are the major phospholipids of S. aureus (31); un-
modified PG and the dimer (DPG) constitute 38–76% and
5–30% of the total phospholipids, respectively, and be-
tween 14 and 38% represent PG esterified with l-lysine
(lysylphosphatidylglycerol [L-PG]; references 31 and 32).
Upon hydrolysis, the lipid from the larger TLC spot was
analyzed by GC-MS and found to contain all expected
components of L-PG. Moreover, l-lysine was the sole
amino acid detected. The total amounts of l-lysine and of
fatty acids in the TLC spot were 1.9 and 3.4 3 1025
mmol, respectively, corresponding reasonably well with
the theoretical molar ratio of 1:2 for L-PG (Fig. 4 B). S.
aureus has previously been shown to produce a variety of
fatty acids, some of which are unsaturated and/or branched
and ranging from 14 to 20 carbon atoms (33), randomly
incorporated into the membrane lipids. Accordingly, we
detected several fatty acids, with branched C15 and C17
members predominating (data not shown). Moreover,
both positional isomers of glycerol monophosphate along
with minor amounts of free glycerol and phosphate were
identified (data not shown), indicating an incomplete hy-
drolysis of the phosphodiester bonds. FT-ICR-MS analysis
of the nonhydrolyzed sample revealed a series of masses
with differences of 14 (Fig. 4 C), which fit well with the
calculated masses of L-PG esterified with fatty acids with
total carbon atom numbers between 29 and 35 (Table II).
Taken together, these results demonstrate that the lipid
lacking in the mprF mutant is L-PG and that mprF is essen-
tial for L-PG biosynthesis. FT-ICR-MS of the minor TLC
spot revealed the same masses as found in the larger spot.
We assume that it represents an L-PG isomer bearing the
Figure 4. Detection of membrane lipids (A),
structure (B), and mass spectrometry analysis (C) of
L-PG. (A) The polar lipids from S. aureus Sa113 wild
type, mprF mutant, and mutant complemented with
pRBmprF were analyzed by 2d-TLC. The first panel
shows the position of the lipids DPG, PG, L-PG,
and the putative 29 L-PG isomer (L-PG2). Two un-
identified lipids were negative (P2N2) or positive
(P1N1) with both phosphate- or amino group–spe-
cific reagents, respectively. (B) Structure of L-PG.
(C) Part of the FT-ICR mass spectrogram of the
TLC spot lacking in the mprF mutant. The molecu-
lar masses of singly protonated ions (m/z) are given
above the peaks. The major peaks represent L-PG
species with two saturated fatty acids (indicated with
a dot; compare Table II). The minor peaks represent
species with one unsaturated fatty acid (mass differ-
ence of 22) or molecules containing one or two 13C
atoms (mass differences of 11 or 12).
Table II. Experimentally Determined and Calculated Masses of 
L-PG in Relation to the Fatty Acid Composition
Total carbon atom 
number of
both fatty acids
Calculated masses
of L-PG*
(MH1)‡
Experimental
masses
(MH1)‡
29 809.56507 809.5654
30 823.58072 823.5795
31 837.59637 837.5943
32 851.61202 851.6075
33 865.62767 865.6233
34 879.64332 879.6408
35 893.65897 893.6546
*Only the masses of saturated fatty acids are considered.
‡MH1, masses of the singly protonated ions.1073 Peschel et al.
lysyl group at the 29 rather than the 39 position (Fig. 4 B).
This isomer has been shown to arise spontaneously from
the 39 species (34) and to migrate slightly differently in 2d-
TLC (35).
MprF-deficient Cells Bind More Antimicrobial Peptides.
Whereas PG and DPG are negatively charged and attract
cationic antimicrobial peptides to the cytoplasmic mem-
brane surface, the lysinylated PG bears a net positive charge
reducing attractive electrostatic interaction (Fig. 5 B). To
analyze whether L-PG–containing bacterial cells accumu-
late less cationic peptide, the capacity of wild-type and
mprF mutant cells to bind Lys(eDns)-tachyplesin 1, a syn-
thetic fluorescent-labeled derivative of tachyplesin 1, was
determined. The modification of tachyplesin 1 caused a
2.5-fold increase in the MIC, but the mprF mutant was still
33-fold more sensitive to the peptide than the wild type
(Fig. 2). Whole cells were incubated with Lys(eDns)-tachy-
plesin 1 and the amount remaining in the supernatant after
centrifugation was determined spectrofluorometrically. In
the supernatants of wild-type cells, a considerably higher
amount of tachyplesin 1 was detected compared with that
found in supernatants of the mutant strain (Fig. 5 A), indi-
cating that in the presence of L-PG, antimicrobial peptides
bind less efficiently to the cells. The wild-type and mutant
bacteria were not killed by Lys(eDns)-tachyplesin 1 at the
concentration used. Similar results were obtained when
bacteria were incubated with gallidermin and the concen-
tration of unbound lantibiotic was determined by RP-
HPLC. Moreover, complementation of the mprF-deficient
mutant with plasmid pTXmprF restored bacterial repulsion
of gallidermin (Fig. 5 A).
mprF-related Genes Are Present in Several Pathogens. The
two mprF genes share similarity with open reading frames
of unknown function from several other bacteria compris-
Figure 5. Increased binding
of antimicrobial peptides in the
absence of L-PG (A) and puta-
tive mode of action of the resis-
tance system (B). (A) S. aureus or
S. xylosus wild-type strains
(black bars) and mprF mutants
(white bars) were incubated
with a fluorescent variant of tac-
hyplesin 1 or gallidermin. The
amount of unbound tachyplesin
1 or gallidermin in the superna-
tants was determined. In binding
studies with gallidermin, mu-
tant strains bearing the mprF
gene on the plasmid pTXmprF
(shaded bars) were also tested,
whereas the wild-type and mutant strains contained the empty control plasmid pTX16. The means and SD of three independent experiments are
shown. (B) The staphylococcal cell wall and membrane are shown. The hydrophobic and positively charged portions of antimicrobial peptides are in-
dicated in gray and white, respectively. A major amount of membrane lipids is esterified with l-lysine residues in wild-type bacteria. The positively
charged l-lysyl groups cause a reduced binding capacity of the cell envelope for cationic antimicrobial peptides, whereas mutant cells lacking L-PG ac-
cumulate the harmful molecules in the membrane composed mainly of negatively charged lipids.
Figure 6. Alignment of the
COOH-terminal 310 amino ac-
ids of the S. aureus MprF protein
(Sa) with the corresponding parts
of hypothetical proteins from S.
xylosus (Sx), B. subtilis (Bs), E.
faecalis (Ef), P. aeruginosa (Pa), A.
tumefaciens (At), S. coelicolor (Sc),
M. tuberculosis (Mt), and M. leprae
(Ml). Identical or similar amino
acids are highlighted in black or
gray, respectively. The COOH-
terminal ends are indicated by
asterisks. The amino acid posi-
tions, calculated from the first
possible start points, are given,
except for the E. faecalis and A.
tumefaciens proteins whose entire
sequences are not yet available.
The mprF sequences from S. au-
reus and S. xylosus are available
from GenBank/EMBL/DDBJ
under accession nos. AF145699
and AF145698, respectively.1074 Staphylococcus aureus Resistance to Defensins via a Novel Virulence Factor
ing the human pathogens P. aeruginosa, Mycobacterium tuber-
culosis, Mycobacterium leprae, E. faecalis, (Fig 6), Bacillus an-
thracis, and Corynebacterium diphtheriae, and the plant
pathogens Agrobacterium tumefaciens and Xylella fastidiosa
(data not shown). The deduced amino acid sequences ex-
hibit very similar hydrophobicity profiles but the myco-
bacterial mprF homologues appear to lack some of the pu-
tative transmembrane segments. Whereas the hydrophobic
NH2-terminal parts of the proteins reveal only limited se-
quence similarity, the hydrophilic COOH-terminal por-
tions are 40–83% similar to MprF of S. aureus (Fig. 6). In
most organisms bearing mprF-related genes, the genetic
context is different and the genes are not encoded within
operons.
Discussion
MprF is a novel virulence factor involved in the S. aureus
escape from innate host defenses. The attenuated virulence
in mice of the mprF mutant was reflected in increased sus-
ceptibility to neutrophil killing and in vitro sensitivity to
defensins, whereas MPO-dependent killing was not af-
fected. Our data thus demonstrate the important role of de-
fensin resistance in S. aureus pathogenicity.
The mprF mutant no longer produces the unusual L-PG
lipid that arises from esterification of PG with l-lysine
(36). It remains to be determined whether mprF encodes
the as yet unidentified L-PG synthase or whether it is in-
volved in some other essential aspect of L-PG biosynthesis.
The putative membrane location of MprF is consistent
with a role in lipid metabolism. Positively charged L-PG
accounts for up to 38% of the S. aureus membrane lipids,
whereas the other phospholipids (PG and DPG) are nega-
tively charged. Therefore, L-PG synthesis most probably
has a significant impact on membrane surface charge and
interactions with cationic antimicrobial peptides, which
have to bind to the charged head groups of the membrane
lipids before integration into the hydrophobic core of the
cytoplasmic membrane (Fig. 5 B). Accordingly, the mprF
mutant was much more susceptible to a broad variety of
cationic antimicrobial peptides whereas the neutral grami-
cidin D was equally active toward wild-type and mprF mu-
tant. The increased binding capacity of mutant cells for a
tachyplesin 1 derivative and gallidermin demonstrates that
the presence of L-PG leads to reduced attraction and bind-
ing of cationic antimicrobial peptides by the bacteria. We
have recently demonstrated that reducing the negative
charge of the staphylococcal cell wall by modification of
the teichoic acid polymers with d-alanine affects the bind-
ing of cationic peptides (3), supporting the notion that S.
aureus cells protect themselves against host defense peptides
by modulating the electrostatic properties of their cell en-
velope. The location of mprF proximal to an S. aureus ho-
mologue of msrA, a locus involved in repair of bacterial
proteins damaged by reactive oxygen species (28), indi-
cates a clustering of genes involved in the escape from
phagocyte functions.
Up to 60% of healthy individuals are permanently or in-
termittently colonized by S. aureus, and carriage is an im-
portant risk factor for life-threatening infections in patients
undergoing surgery, bearing intravascular devices, or those
with HIV infection and AIDS (37). The main ecological
niches for S. aureus are the nasal epithelia, although these
sites are protected by defensins produced by epithelial cells
and submucosal glands (38). Defensin resistance thus may
play a key role in the capacity of S. aureus to infect host tis-
sues, in particular those of cystic fibrosis or chronic granu-
lomatous disease patients (6, 8). It should be noted that S.
aureus produces L-PG in comparatively high amounts,
whereas coagulase-negative staphylococci contain only
traces (Staphylococcus epidermidis, S. xylosus) or no detectable
amounts (Staphylococcus haemolyticus, Staphylococcus saprophyt-
icus) of this unusual lipid (26). It is tempting to speculate
that high L-PG content is a prerequisite for S. aureus sur-
vival on nasal epithelia and invasiveness.
Lysinylation of phospholipids may play a similar role in
other bacteria. L-PG has been described in several bacterial
species bearing mprF-related genes including E. faecalis, B.
subtilis (39), and P. aeruginosa (40). In the remaining bacte-
ria with mprF homologues, the membrane lipids seem to be
only incompletely characterized (41). Defensin-like pep-
tides also play a role in the defense of plants against micro-
bial infections (10), perhaps explaining the presence of a
mprF homologue adjacent to other virulence genes in the
plant pathogen A. tumefaciens (42). MprF thus represents an
interesting new target for novel antimicrobial drugs which
block L-PG synthesis and thereby render the bacteria sus-
ceptible to antimicrobial host defenses.
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